Recall

123. Recall Alert (Class-I) – Drug Products (Human) Substandard – Gligit Baltistan.

Salateen Philip Recall Alerts December 18, 2025December 18, 2025Recall

Recall Alert

Download

DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUGS TESTING LABORATORY.

DRAP Alert No	No II/S/12-25-123
Action Date	18 December, 2025.
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Drugs, Water & Food Testing Laboratory, Government of Gilgit Baltistan informed that the samples of below mentioned drug products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#	Product Name	Batch No.	Remarks	Manufacturers
1.	Glitric Tablets Each prolonged release tablet contains: Glyceryl Trinitrate …………… 2.6 mg (Reg. # 119607)	25H261 & 25H262	Batch # 25H261 The sample has been declared “Substandard” on the basis of Assay & Dissolution Test.   Batch # 25H262 The sample has been declared “Substandard” on the basis of Assay Test.	M/s Linta Pharmaceuticals. Plot # 03, Street S-5, National Industrial Zone, Rawat, Islamabad. (DML # 000810)
2.	Betahist Tablet Each Tablet contains: Betahistine DiHydrochloride … 16 mg (Reg. 091595)	25H249	The sample has been declared “Substandard” on the basis of Physical description. (Tablets found with softening, cracking, rough orange peel texture, easily break, and become powder when pressed with fingers).

Risk Statement:	The identified quality defects in Glyceryl Trinitrate prolonged-release tablets (Glitric 2.6 mg), including failure of assay and dissolution, and the severe physical instability observed in Betahistine tablets (Betahist 16 mg) may result in therapeutic failure and unpredictable dosing. Glyceryl Trinitrate is a critical cardiovascular medicine with a sensitive therapeutic window, and inadequate dosing may precipitate angina or serious ischemic events, particularlyinelderly patients and those with ischemic heart disease. Betahistine defects may lead to loss of efficacy in patients suffering from vertigo and balance disorders. The public most likely to be affected includes chronic cardiovascular and vestibular disorder patients, especially the elderly and comorbid populations.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.   -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

120. Recall Alert (Class-I) – Drug Products (Human) Substandard by DTL Punjab.

Salateen Philip Recall Alerts December 16, 2025December 16, 2025Recall

Recall Alert

Download

DRUG PRODUCTS DECLARED SUBSTANDARD BY DRUG TESTING LABORATORIES PUNJAB.

DRAP Alert No	No II/S/12-25-120
Action Date	16 December, 2025.
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Drug Testing Laboratories, Punjab informed that the sample of below mentioned drug products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	Injection Neudex Dexamethasone Sodium Phosphate eq. to Dexamethasone Phosphate: 4mg/ml (Reg. # 32876)	DX029, DX039, DX040, DX041, DX033, DX031, DX045, DX042, DX044, DX046, DX047, DX048, DX049, DX050, DX051, DX053, DX052, DX060, DX059.	M/s Neutro Pharma (Pvt) Ltd. 9.5-Km Sheikhupura Road Lahore. (DML # 000576)	The sample is declared as “Adulterated” as per section 3 (iv) of The Drugs Act 1976.
2.	Injection Ame-Pin Each 2ml contains: Tramadol HCI… 100 mg (Reg. # 065943)	TD-042	M/s Ameer Pharma (Pvt) Ltd. 23-Km Sheikhupura Road, Lahore. (DML # 000604)	The sample “Sub-Standard” on the basis “Particulate contamination” visible particles” as per BP.

Risk Statement:	The use of Injection Neudex (Dexamethasone) declared as adulterated, and Injection Ame-Pin (Tramadol) found sub-standard due to visible particulate contamination, poses a serious risk to patient safety, particularly among critically ill patients, surgical patients, emergency care recipients, elderly individuals, and those with compromised immunity. Administration of adulterated or contaminated injectable products may result in treatment failure, severe allergic reactions, embolism, infections, organ toxicity, or even fatal outcomes. Healthcare professionals and patients are therefore urged to immediately discontinue use of the affected batches to prevent any potential adverse health consequences.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.   -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

119. Recall Alert (Class-II) – Drug Products (Human) Substandard -DTL Punjab

Salateen Philip Recall Alerts December 16, 2025December 16, 2025Recall

Recall Alert

Download

DRUG PRODUCTS DECLARED SUBSTANDARD BY DRUG TESTING LABORATORIES PUNJAB.

DRAP Alert No	No II/S/12-25-119
Action Date	16 December, 2025.
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Drug Testing Laboratories, Punjab informed that the sample of below mentioned drug products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	Tablet Ascard 75 mg Each Enteric Coated Tablet Contains: Acetylsalicylic Acid (Aspirin BP) ….75mg (Reg. # 016600)	AR034L	M/s Atco Laboratories Limited, B-18 S.I.T.E Karachi. (DML # 000537)	The sample is declared as “sub-standard” on the basis of Test for Related Substances (Impurity C: Salicylic Acid).
2.	Sachet PREVASMA  Each Sachet Contains: Montelukast Sodium USP eq. to Montelukast …………………………….. 4.0 mg (Reg. # 074838)	033	M/s MKB Pharmaceuticals (Pvt) Ltd. 66-Hayatabad Industrial Estate Jamrud Road Peshawar. (DML # 000617)	The sample is declared as “sub-standard” on the basis of Test for Impurities i.e. Organic Impurities.

Risk Statement:	The use of the above-mentioned sub-standard therapeutic goods may pose a potential risk to public health, particularly among patients requiring regular and long-term therapy. Tablet Ascard 75 mg is commonly prescribed for cardio-protective purposes, especially in patients with ischemic heart disease, history of stroke, hypertension, and diabetes, where the presence of excess Salicylic Acid impurity may increase the risk of gastro-intestinal irritation, bleeding tendencies, and hypersensitivity reactions. Similarly, Sachet PREVASMA (Montelukast 4 mg) is primarily used in children and patients with asthma and allergic conditions, and the presence of organic impurities beyond specified limits may lead to reduced therapeutic efficacy, unexpected adverse reactions, or worsening of respiratory symptoms. Therefore, children, elderly patients, cardiac patients, asthmatics, and individuals on chronic medication represent the population most likely to be affected, and immediate regulatory action including recall, market monitoring, and patient safety communication is warranted to mitigate potential health risks.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.   -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

118. Recall Alert (Class-I) – DTLs Punjab declared Substandard products (Human)

Salateen Philip Recall Alerts December 8, 2025December 8, 2025Recall

Recall Alert

Download

DRUG PRODUCTS DECLARED SUBSTANDARD BY DRUG TESTING LABORATORIES PUNJAB

DRAP Alert No	No I/S/12-25-118
Action Date	08 December, 2025.
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Drug Testing Laboratories Punjab informed that the sample of below mentioned drug product has been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	AOTILAS 120 ML SUSPENSION Each mL Contains: Domperidone ………. 1 mg (Reg. # 112505)	S8B05	M/s Astellas Pharmaceutical (Pvt) Ltd.  15-C Industrial Estate Hayatabad Peshawar. (DML # 000677)	The sample is “Substandard” as it contains the impurity “Diethylene Glycol” above the permissible limit.
2.	Injection. Neudex Dexamethasone Sodium Phosphate eq. to Dexamethasone Phosphate: 4mg/ml (Reg. # 32876)	DX032, DX034, DX035 & DX036	M/s Neutro Pharma (Pvt) Ltd.  9.5-Km Sheikhupura Road Lahore. (DML # 000576)	The sample is declared as “Adulterated” as per section 3 (iv) of The Drugs Act 1976.

Risk Statement:	The substandard quality of AOTILAS 120 mL Suspension containing Diethylene Glycol (DEG) above the permissible limit, and the adulterated status of Neudex Injection (Dexamethasone) pose a severe and immediate threat to public health. The populations most likely to be affected include infants, children, elderly patients, pregnant women, and critically ill patients who are prescribed these medicines for gastrointestinal disorders, inflammation, allergic reactions, and emergency medical conditions. Exposure to Diethylene Glycol is highly toxic and may cause acute kidney failure, neurological damage, metabolic acidosis, and death, especially in pediatric patients.   The use of an adulterated injectable corticosteroid significantly increases the risk of systemic toxicity, treatment failure, severe infections, shock, and fatal outcomes. Continued availability or use of these products may lead to rapid deterioration of patient health, mass poisoning incidents, irreversible organ damage, and loss of life, representing a highest-level public health emergency requiring immediate recall and strict regulatory enforcement.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.   -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

117. Recall Alert (Class-II) – DTLs Punjab Declared Substandard Drug Products.

Salateen Philip Recall Alerts December 8, 2025December 8, 2025Recall

Recall Alert

Download

DRUG PRODUCTS DECLARED SUBSTANDARD BY DRUG TESTING LABORATORIES PUNJAB.

DRAP Alert No	No I/S/12-25-117
Action Date	08 December, 2025.
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Drug Testing Laboratories, Punjab informed that the sample of below mentioned drug products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	Tablet Virtec 10 mg Each Tablet Contains: Cetrizine Dihydrochloride 10mg	FK-25-001	M/s Don Valley Pharmaceuticals (Pvt) Ltd. 31-Km Ferozepur Road Lahore. (DML # 000395)	The sample is Substandard on the for Organic Impurities, performed as per USP.
2.	Tablet Megadip 5mg Each Tablet Contains: Amlodipine as Besylate ….  5mg (Reg. # 32876)	25G337	M/s Mega Pharmaceuticals Ltd. 27 Km Raiwind Road Lahore. (DML # 000537)	The sample is declared as “Sub-Standard” on the basis of Test for Impurities (Organic Impurities).

Risk Statement:	The substandard quality of Tablet Virtec 10 mg (Cetirizine) and Tablet Megadip 5 mg (Amlodipine) due to failure in organic impurities testing poses a significant risk to public health. The populations most likely to be affected include patients suffering from allergies, hypertension, and cardiovascular diseases, particularly elderly individuals, children, and patients with chronic illnesses who regularly depend on these medicines for symptom control and disease management. The presence of excessive or unidentified organic impurities may lead to reduced therapeutic effect, unexpected side effects, toxic reactions, or long-term health complications. Continuous use of such substandard medicines may result in treatment failure, worsening of disease conditions, hospitalization, and in severe cases, life-threatening outcomes, thereby representing a serious public health concern.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.   -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

116. Recall Alert (Class-II)- Drug Products declared Substandard.

Salateen Philip Recall Alerts November 27, 2025November 27, 2025Recall

Recall Alert

Download

DRUG PRODUCTS DECLARED SUBSTANDARD BY CENTRAL DRUGS LABORATORY KARACHI.

DRAP Alert No	No I/S/11-25-116
Action Date	27 November, 2025.
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Provincial Drug Testing Laboratories informed that the sample of below mentioned drug product has been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	Tablet Sapizine 10 mg Each Tablet Contains: Cetrizine Dihydrochloride …. 10mg (Reg. # 054261)	13028	M/s Sapient Pharma, 123-S Industrial Area Kot Lakhpat Lahore. (DML # 000207)	The sample has been declared substandard on the basis of Impurities Test (Organic Impurities).
2.	Tablet ORTIZIN 10mg Each Tablet Contains: Cetrizine Dihydrochloride …. 10mg (Reg. # 025405)	25C052	M/s Obsons Pharmaceuticals.  209-S Industrial Estate Kot Lakhpat Lahore. (DML # 000416)	The sample has been declared substandard on the basis of Impurities Test (Organic Impurities).

Risk Statement:	Use of medicines containing excessive organic impurities may lead to reduced therapeutic effect, unpredictable adverse reactions, allergic responses, or toxicity, particularly in sensitive individuals such as children, pregnant women, and elderly patients. Since these products are commonly used for allergy related conditions, a large portion of the public, including patients self-medicating with over-the-counter antihistamines is most likely to be affected. Immediate discontinuation of the affected batches is advised to prevent potential harm.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.   -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

115. Recall Alert (Class-I) Veterinary Drug Product declared Substandard.

Salateen Philip Recall Alerts November 27, 2025November 27, 2025Recall

Recall Alert

Download

VETERINARY DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG LABORATORIES, KARACHI.

DRAP Alert No	No I/S/11-25-115
Action Date	27 November, 2025.
Target Audience	·         National Regulatory Field Force of DRAP and Provincial Drug Control Departments. ·         Healthcare Professionals-Veterinarians ·         Farmers/consumers
Problem / Issue	Provincial Drug Testing Laboratories, Punjab informed that the sample of below mentioned Veterinary Drug products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#	Product Details	Batch #	Manufacturer details	Remarks
1.	Tribrissen Injection 48% Each 100ml vial contains: Trimethoprim, BP…….8%w/v Sulfadiazine, BP…..40%  (Reg. #  091891)	157884	M/s Hilton Pharma (Pvt) Ltd.    Plot No. 13 & 14 Sector 15 Korangi Industrial Area Karachi. (DML # 000543)	The sample  sample is Sub-Standard, on the basis Assay and Sterility Tests performed as per BP.

Risk Statement:	Use of a non-sterile or sub-potent veterinary injectable poses a significant risk of severe local infections, fever, systemic illness, treatment failure, and increased mortality in treated animals. Animals receiving ineffective therapy may continue to carry and spread infections, increasing the likelihood of disease transmission within herds. In addition, animals that develop injection-site abscesses or systemic reactions may produce unsafe milk or meat, posing a public-health risk, particularly where veterinary medicines enter the food chain without adequate withdrawal periods. The public most likely to be affected include farmers, livestock handlers, consumers of raw milk/meat, and community’s dependent on these animals for food or livelihood.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Veterinarian	This alert applies strictly to the specific batches listed above and does not apply to other batches of the same products. Veterinarians are therefore advised not to prescribe, administer, or stock these identified batches under any circumstances. In case any of the above-mentioned batches have already been administered, treated animals should be closely monitored for possible signs of infection, treatment failure, or adverse reactions, and appropriate supportive care must be provided. Any suspected adverse events or quality-related problems linked to these batches should be reported immediately to DRAP’s Pharmacovigilance Centre and to the Provincial Livestock & Dairy Development Departments. Practitioners are further advised to ensure that only alternative registered and quality-assured batches are used in veterinary practice.
Advice for Farmers and Livestock Owners	Farmers and livestock owners are advised to immediately stop using the affected batch and isolate all remaining stock. Closely monitor treated animals for fever, swelling at the injection site, reduced appetite, or any sudden illness, and consult a veterinarian if such symptoms appear. Until animals are clinically stable, avoid selling or using milk or meat from visibly unwell animals. The affected product should be returned to the supplier or distributor according to recall instructions. Farmers are further advised to maintain proper records of batch numbers, treatment dates, and suppliers for traceability, and to ensure that only sterile, approved veterinary injections are used and stored under recommended conditions.

114. Recall Alert (Class-I) – Injection Cyanofar 50ml (Veterinary) – Substandard

Salateen Philip Recall Alerts November 21, 2025November 21, 2025Recall

Recall Alert

Download

VETERINARY DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG LABORATORIES, KARACHI.

DRAP Alert No	No I/S/11-25-114
Action Date	21 November, 2025.
Target Audience	·         National Regulatory Field Force of DRAP and Provincial Drug Control Departments. ·         Healthcare Professionals-Veterinarians ·         Farmers/consumers
Problem / Issue	Drugs Testing Laboratories from Provinces informed that the sample of below mentioned Veterinary Drug products have been declared as ‘Substandard ’.

Therapeutic Goods (s) Affected: –

S#	Product Details	Batch #	Manufacturer details	Remarks
1.	Injection Cyanofar 50 ml Each ml Contains: Cyanocobalamin….125mcg (Reg. # 074745)	CY-2431	M/s Izfaar Pharmaceutical Industries.   542/A-B Sunder Industrial Estate Lahore (DML # 000800)	The above sample is “Sub-Standard”, on the basis of Sterility Test performed as per USP.

Risk Statement:	The above veterinary injectable product has been declared Substandard due to failure in the Sterility Test, indicating a risk of microbial contamination. Use of a non-sterile injectable in animals may lead to serious infections, treatment failure, or mortality. Livestock farmers, dairy producers, veterinarians, and animal handlers are the groups most likely to be affected, as contaminated therapy can result in animal illness, reduced productivity, economic losses, and potential downstream public-health concerns linked to milk and meat safety.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Veterinarian	This alert applies strictly to the specific batches listed above and does not apply to other batches of the same products. Veterinarians are therefore advised not to prescribe, administer, or stock these identified batches under any circumstances. In case any of the above-mentioned batches have already been administered, treated animals should be closely monitored for possible signs of infection, treatment failure, or adverse reactions, and appropriate supportive care must be provided. Any suspected adverse events or quality-related problems linked to these batches should be reported immediately to DRAP’s Pharmacovigilance Centre and to the Provincial Livestock & Dairy Development Departments. Practitioners are further advised to ensure that only alternative registered and quality-assured batches are used in veterinary practice.
Advice for Farmers and Livestock Owners	Farmers and livestock owners are advised to immediately stop using the affected batch and isolate all remaining stock. Closely monitor treated animals for fever, swelling at the injection site, reduced appetite, or any sudden illness, and consult a veterinarian if such symptoms appear. Until animals are clinically stable, avoid selling or using milk or meat from visibly unwell animals. The affected product should be returned to the supplier or distributor according to recall instructions. Farmers are further advised to maintain proper records of batch numbers, treatment dates, and suppliers for traceability, and to ensure that only sterile, approved veterinary injections are used and stored under recommended conditions.

113. Recall Alert (Class-I) – Substandard Drug Products (Human)

Salateen Philip Recall Alerts November 20, 2025December 8, 2025Recall

Recall Alert

Download

DRUG PRODUCTS DECLARED SUBSTANDARD BY DRUG TESTING LABORATORIES PUNJAB.

DRAP Alert No	No I/S/11-25-113
Action Date	20 November, 2025.
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Provincial Drug Testing Laboratories informed that the sample of below mentioned drug product has been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	Injection Freclomide Each Ampoule contains Metoclopramide HCl ……10mg (Reg. # 071331)	25MC09	M/s Friends Pharma (Pvt) Ltd. 31-Km Ferozepur Road Lahore. (DML # 000531)	The above sample is Sub-Standard on the basis of “Particulate contamination: visible particles” performed as per BР.
2.	Infusion SAFEMED Each 100ml contains: Metronidazole ……….. 500mg (Reg. # 045824)	SAU-2501	M/s Ahad International Pharmaceutical Limited. 13-Km Gomal University Multan Road Dera Ismail Khan. (DML # 000433)	The above sample is Sub-Standard, on the basis of Particulate contamination: visible particles performed as per BP.
3.	Tablet Loratamin Each Tablet Contains: Loratadine …. 10mg (Reg. #  062647)	23	M/s Murfy Pharmaceuticals (Pvt) Ltd.  8-Km Raiwind Road Lahore. (DML # 000543)	The sample is “Adulterated” as defined under clause (iv) of sub-section (a) of section 3 of The Drugs Act, 1976 as it contains “Paracetarmol” as an ingredient a substance other than the prescribed substance i.e., Loratadine.

Risk Statement:	All three products present a high public health risk due to critical quality defects. Injection Freclomide and Infusion SAFEMED contain visible particulate contamination, which can lead to severe reactions such as embolism, sepsis, organ damage, or death, especially when administered intravenously. Tablet Loratamin is adulterated with Paracetamol, exposing patients to incorrect therapy, potential allergic reactions, and failure to treat the intended condition. The population most likely to be affected includes acutely ill patients in hospitals, emergency departments, and general public using these medicines for routine treatment, placing them at a heightened risk of adverse outcomes due to compromised product quality.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.   -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

112. Recall Alert (Class-I) – Veterinary Drug Products (Substamdard)

Salateen Philip Recall Alerts November 18, 2025November 18, 2025Recall

Recall Alert

Download

VETERINARY DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG LABORATORIES, KARACHI.

DRAP Alert No	No I/S/10-25-111
Action Date	18 November, 2025.
Target Audience	·         National Regulatory Field Force of DRAP and Provincial Drug Control Departments. ·         Healthcare Professionals-Veterinarians ·         Farmers/consumers
Problem / Issue	Drugs Testing Laboratories from Provinces informed that the sample of below mentioned Veterinary Drug products have been declared as ‘Substandard ’.

Therapeutic Goods (s) Affected: –

S#	Product Details	Batch #	Manufacturer details	Remarks
1.	Injection Antil 50 ml Each ml Contains: Pheniramine maleate …… 11.35mg (Reg. # 074750)	AN-2520 & AN-2519	M/s Izfaar Pharmaceutical Industries.   542/A-B Sunder Industrial Estate Lahore (DML # 000800)	The sample is declared as “Sub-Standard” on the basis of Assay Test and Sterility Test.
2.	Injection Mac Rold 2% 50 ml Each ml contains: Ivermectin …. 20 mg (Reg # 106810)	YI-140	M/s Haarlods Pharmaceuticals (Pvt) Ltd. Plot No.60-64/C, Small Industrial Estate, Bhimber, AJK. (DML # 000921)	The sample is declared as “Sub-Standard” on the basis of Assay Test and Related substances.

Risk Statement:	The above veterinary injectable products have been declared Substandard on the basis of critical quality failures, including Assay, Chromatographic Purity/Related Substances, and Sterility tests. Use of such defective veterinary injections poses a significant risk of treatment failure, toxicity, adverse reactions, and severe infections in animals. The groups most likely to be affected include livestock farmers, dairy producers, animal handlers, and veterinarians, as compromised product quality may lead to animal morbidity or mortality, reduced productivity, contamination of milk or meat, and consequential economic losses. These defects may also indirectly impact public health, particularly where contaminated or inadequately treated animals enter the food supply chain.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Veterinarian	This alert applies strictly to the specific batches listed above and does not apply to other batches of the same products. Veterinarians are therefore advised not to prescribe, administer, or stock these identified batches under any circumstances. In case any of the above-mentioned batches have already been administered, treated animals should be closely monitored for possible signs of infection, treatment failure, or adverse reactions, and appropriate supportive care must be provided. Any suspected adverse events or quality-related problems linked to these batches should be reported immediately to DRAP’s Pharmacovigilance Centre and to the Provincial Livestock & Dairy Development Departments. Practitioners are further advised to ensure that only alternative registered and quality-assured batches are used in veterinary practice.
Advice for Farmers and Livestock Owners	Farmers, livestock owners, and veterinary practitioners are advised not to use the affected batches of the above-mentioned injectable veterinary products found Substandard due to failures in Assay, Sterility, Chromatographic Purity, and Related Substances tests. Use of such defective injections may result in ineffective treatment, unexpected adverse reactions, infections, toxicity, or deterioration in the animal’s health and productivity. Immediately stop administration, isolate remaining stock, and return it to your supplier or distributor. If any animal has already received these injections, monitor for unusual symptoms such as fever, swelling at the injection site, allergic reactions, or treatment failure, and consult a qualified veterinarian without delay. Livestock handlers, dairy owners, and farmers are further advised to ensure that only quality-assured and properly stored veterinary medicines are used for animals to protect herd health, avoid economic loss, and prevent contamination of milk and meat entering the food chain.

• ← Previous